News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue Guidance for EXONDYS 51® (eteplirsen), Representing Approximately 100 Percent Year-over-Year Growth
-- Fourth quarter 2017 EXONDYS 51 unaudited revenue of $57.3 million -- -- Full-year 2017 EXONDYS 51 unaudited revenue of $154.6 million -- -- Full-year 2018 EXONDYS 51 revenue guidance of $295 – $305 million -- -- 16 programs in development -- SAN FRANCISCO , Jan.
View HTML
Toggle Summary Sarepta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management will present at
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Dec. 29, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, granted equity awards on December 29, 2017 , that
View HTML
Toggle Summary Sarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated Patients Compared to Natural History of Duchenne Muscular Dystrophy in The Journal of Neuromuscular Diseases
CAMBRIDGE, Mass. , Dec. 27, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that the pulmonary function
View HTML
Toggle Summary Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors
CAMBRIDGE, Mass. , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the election of biopharmaceutical
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, granted equity awards on November 30, 2017 , that
View HTML
Toggle Summary Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes Due 2024
-- Capped call transactions raise the effective conversion price of the notes to $104.88, subject to future adjustments -- CAMBRIDGE, Mass. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and
View HTML
Toggle Summary Sarepta Therapeutics Prices $475 Million of Convertible Senior Notes Due 2024
-- Chief executive officer purchases approximately $2 million of shares of Sarepta’s common stock -- CAMBRIDGE, Mass. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision
View HTML
Toggle Summary Sarepta Therapeutics Announces Proposed Offering of $375 Million of Convertible Senior Notes Due 2024
Chief executive officer indicates interest in purchasing $2 million of shares of Sarepta's common stock CAMBRIDGE, MA -- (Marketwired) -- 11/07/17 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) , a commercial-stage biopharmaceutical company focused on the discovery and development of precision
View HTML
Toggle Summary Sarepta Therapeutics Announces FDA Clearance of IND for the Company’s PPMO Exon 51 Candidate, SRP-5051
-- Sarepta to immediately initiate a Phase 1/2a clinical trial in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51 -- CAMBRIDGE, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.